Experimental One-Dose Blood Thinner Abelacimab Could Slash Blood Clot Risk After Knee Replacement

experimental one dose blood thinner abelacimab could slash blood clot risk after knee replacement

Sumary of Experimental One-Dose Blood Thinner Abelacimab Could Slash Blood Clot Risk After Knee Replacement:

  • By Ernie Mundell and Robert Preidt HealthDay ReportersTUESDAY, July 20, 2021 — Anyone who’s ever undergone knee replacement understands the real and troubling risk of post-op blood clots.
  • Many patients are told take a daily blood thinner pill long after their procedure.
  • But a new study finds that a one-time injection of an experimental blood thinner called abelacimab may greatly reduce the odds for these clots in recovering knee replacement patients.
  • The researchers compared abelacimab with another prescription blood thinner called enoxaparin (brand name Lovenox) in 412 patients undergoing knee replacement.
  • Compared to enoxaparin, a single injection of abelacimab reduced the risk of blood clots by 80% for up to a month after surgery, and didn’t increase the risk of bleeding — a common side effect with blood thinners.
  • “Patients who undergo knee replacement routinely receive anti-clotting treatment with enoxaparin or other anticoagulant medications that require daily administration,” said research team leader Jeffrey Weitz.
  • According to the research team, abelacimab is an antibody that binds to both the inactive and activated forms of a clotting factor called factor XI, preventing its activation and activity, and halting clot formation.
  • This drug could be applied not only to total joint replacement, but also to fracture treatment.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.